# ZUMA-1 (NCT02348216)

> Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02348216
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Kite, A Gilead Company
- Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL); Relapsed Diffuse Large B-Cell Lymphoma; Transformed Follicular Lymphoma (TFL); Primary Mediastinal B-cell Lymphoma (PMBCL); High Grade B-cell Lymphoma (HGBCL)
- Interventions: Axicabtagene Ciloleucel; Fludarabine; Cyclophosphamide; Levetiracetam; Tocilizumab; Dexamethasone; High-dose methylprednisolone; Bendamustine; Rituximab; Doxorubicin; Prednisone; Vincristine; Ifosfamide; Carboplatin; Etoposide; Gemcitabine; Oxaliplatin; Cisplatin; Methylprednisolone
- Enrollment: 307
- Primary outcome: Phase 1 Study: Number of Participants Experiencing Adverse Events (AEs) Defined as Dose Limiting Toxicities (DLTs)
- Primary outcome: Phase 2 Pivotal Study (Cohorts 1 and 2): Overall Response Rate (ORR) as Assessed by Investigator Per Revised International Working Group (IWG) Response Criteria for Malignant Lymphoma
- Primary outcome: Phase 2 Safety Management Study (Cohort 3): Percentage of Participants With Treatment-Emergent Cytokine Release Syndrome (CRS) and Neurologic Toxicities by Severity Grades
- Primary outcome: Phase 2 Safety Management Study (Cohort 4): Percentage of Participants With Treatment-Emergent CRS and Neurologic Toxicities by Severity Grades
- Primary outcome: Phase 2 Safety Management Study (Cohort 5): Percentage of Participants With Treatment-Emergent CRS and Neurologic Toxicities by Severity Grades
- Primary outcome: Phase 2 Safety Management Study (Cohort 6): Percentage of Participants With Treatment-Emergent CRS and Neurologic Toxicities by Severity Grades

## Commentary we found

- YouTube: 45
- Podcasts: 38
- X threads: 26

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=zuma-1-nct02348216

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02348216", "email": "<work email>"}; the inbox owner confirms by the emailed link.